Literature DB >> 20515648

IGFBP2 promotes glioma tumor stem cell expansion and survival.

David Hsieh1, Antony Hsieh, Baldassarre Stea, Ron Ellsworth.   

Abstract

IGFBP2 is overexpressed in the most common brain tumor, glioblastoma (GBM), and its expression is inversely correlated to GBM patient survival. Previous reports have demonstrated a role for IGFBP2 in glioma cell invasion and astrocytoma development. However, the function of IGFBP2 in the restricted, self-renewing, and tumorigenic GBM cell population comprised of tumor-initiating stem cells has yet to be determined. Herein we demonstrate that IGFBP2 is overexpressed within the stem cell compartment of GBMs and is integral for the clonal expansion and proliferative properties of glioma stem cells (GSCs). In addition, IGFBP2 inhibition reduced Akt-dependent GSC genotoxic and drug resistance. These results suggest that IGFBP2 is a selective malignant factor that may contribute significantly to GBM pathogenesis by enriching for GSCs and mediating their survival. Given the current dearth of selective molecular targets against GSCs, we anticipate our results to be of high therapeutic relevance in combating the rapid and lethal course of GBM. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20515648     DOI: 10.1016/j.bbrc.2010.05.145

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  34 in total

Review 1.  Complex oncogenic signaling networks regulate brain tumor-initiating cells and their progenies: pivotal roles of wild-type EGFR, EGFRvIII mutant and hedgehog cascades and novel multitargeted therapies.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Brain Pathol       Date:  2011-07-07       Impact factor: 6.508

2.  Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib.

Authors:  Chung H Kok; David T Yeung; Liu Lu; Dale B Watkins; Tamara M Leclercq; Phuong Dang; Verity A Saunders; John Reynolds; Deborah L White; Timothy P Hughes
Journal:  Blood Adv       Date:  2019-05-28

Review 3.  Molecular mechanisms of cancer development in obesity.

Authors:  Melin J Khandekar; Paul Cohen; Bruce M Spiegelman
Journal:  Nat Rev Cancer       Date:  2011-11-24       Impact factor: 60.716

4.  IGF binding protein 2 supports the survival and cycling of hematopoietic stem cells.

Authors:  Hoangdinh Huynh; Junke Zheng; Masato Umikawa; Chaozheng Zhang; Robert Silvany; Satoru Iizuka; Martin Holzenberger; Wei Zhang; Cheng Cheng Zhang
Journal:  Blood       Date:  2011-08-05       Impact factor: 22.113

5.  Cellular and molecular characterization of human cardiac stem cells reveals key features essential for their function and safety.

Authors:  Sadaf Vahdat; Seyed Ahmad Mousavi; Gholamreza Omrani; Maziar Gholampour; Fattah Sotoodehnejadnematalahi; Zaniar Ghazizadeh; Javad Gharechahi; Hossein Baharvand; Ghasem Hosseini Salekdeh; Nasser Aghdami
Journal:  Stem Cells Dev       Date:  2015-06-15       Impact factor: 3.272

Review 6.  Extracellular vesicles shed by glioma cells: pathogenic role and clinical value.

Authors:  Dimitry A Chistiakov; Vladimir P Chekhonin
Journal:  Tumour Biol       Date:  2014-06-27

7.  Glioma progression is mediated by an addiction to aberrant IGFBP2 expression and can be blocked using anti-IGFBP2 strategies.

Authors:  Lynette M Phillips; Xinhui Zhou; David E Cogdell; Corrine Yingxuan Chua; Anouk Huisinga; Kenneth R Hess; Gregory N Fuller; Wei Zhang
Journal:  J Pathol       Date:  2016-06-10       Impact factor: 7.996

Review 8.  IGF-binding protein 2 is a candidate target of therapeutic potential in cancer.

Authors:  Xiaofeng Yao; Shanshan Sun; Xuan Zhou; Wenyu Guo; Lun Zhang
Journal:  Tumour Biol       Date:  2015-12-09

9.  IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells.

Authors:  Haibo Lu; Li Wang; Wen Gao; Jieru Meng; Bingbing Dai; Shuhong Wu; John Minna; Jack A Roth; Wayne L Hofstetter; Stephen G Swisher; Bingliang Fang
Journal:  Mol Cancer Ther       Date:  2013-10-15       Impact factor: 6.261

10.  IGFBP2 promotes vasculogenic mimicry formation via regulating CD144 and MMP2 expression in glioma.

Authors:  Y Liu; F Li; Y T Yang; X D Xu; J S Chen; T L Chen; H J Chen; Y B Zhu; J Y Lin; Y Li; X M Xie; X L Sun; Y Q Ke
Journal:  Oncogene       Date:  2018-10-27       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.